52 Week Range
As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Diaceutics H1 Adjusted EBITDA 300,000 Stg Vs Loss Of 300,000 Stg
Diaceutics Announces New Contract Win For DXRX Platform
Diaceutics Says Sales For First Half Increased By 20%
Diaceutics PLC is a United Kingdom-based data analytics and implementation services company which services the global pharmaceutical industry. The Company offers end to end services that encompasses from understanding the diagnostic landscape to test implementation into treatment pathways to enable better treatment decisions for patients. The Company’s data analytics and implementation services, including Landscape, Tracking, and Primary Market Research, leverages the diagnostic testing information to provide data-driven insights to drive seamless integration of diagnostic tests into treatment pathways. Its implementation services include Planning, Commercialization and Reimbursement Landscapes, to build the strategies and implement the tactics that drives optimal test utilization, ensuring that patients are getting the right treatment.
727 Antrim Road
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
* DIACEUTICS PLC - SALES FOR FIRST HALF INCREASED BY 20 PER CENT. TO £5.3 MILLION Source text for Eikon: Further company coverage:
Britain's FTSE 100 index is seen opening up 22 points to 7,304 on Monday, according to financial bookmakers, with futures trading up 0.5%.
Britain's FTSE 100 index is seen opening up 22 points to 7,304 on Monday, according to financial bookmakers, with futures trading up 0.3% at 7307. * BRITISH AIRWAYS: British Airways pilots began a 48-hour strike on Monday, grounding most of the airline's flights and disrupting...
In the halls of MD Anderson Cancer Center, the drug Vitrakvi is known for having a "Lazarus effect" in some patients because it can reverse late-stage cancer that has defied all other treatment options.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.